Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.92 +3.1%	$6.01	$3.93 ▼ $7.32	$302.87M	1.51	1.09 million shs	823,522 shs
LXRX Lexicon Pharmaceuticals	$1.18 +9.3%	$0.74	$0.28 ▼ $2.45	$426.56M	1.13	9.81 million shs	3.04 million shs
PTGX Protagonist Therapeutics	$55.23 +4.2%	$50.03	$32.50 ▼ $60.60	$3.42B	2.26	994,431 shs	796,417 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs
ULUR ULURU		$0.00	$0.10 ▼ $0.79	$5.35M	-3.13	6,691 shs	N/A

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	-2.78%	-6.82%	+15.96%	+4.17%
LXRX Lexicon Pharmaceuticals	0.00%	+18.68%	+60.83%	+103.77%	-45.45%
PTGX Protagonist Therapeutics	0.00%	+3.52%	-5.98%	+17.70%	+46.73%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
ULUR ULURU	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.7701 of 5 stars	3.5	1.0	0.0	4.5	1.8	2.5	0.0
LXRX Lexicon Pharmaceuticals	2.4113 of 5 stars	3.2	3.0	0.0	0.0	1.5	2.5	0.6
PTGX Protagonist Therapeutics	1.603 of 5 stars	2.5	1.0	0.0	0.0	4.1	2.5	0.0
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	225.17% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	210.73% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	19.68% Upside
REPH Recro Pharma	0.00	N/A	N/A	N/A
ULUR ULURU	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LXRX, REPH, ABEO, PTGX, and ULUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/30/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	86.53	N/A	N/A	$1.01 per share	5.86
LXRX Lexicon Pharmaceuticals	$31.21M	13.67	N/A	N/A	$0.40 per share	2.95
PTGX Protagonist Therapeutics	$434.43M	7.88	$4.71 per share	11.73	$11.33 per share	4.87
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	N/A	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	73.64	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A
ULUR ULURU	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest LXRX, REPH, ABEO, PTGX, and ULUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	N/A	N/A	N/A	$21.71 million	N/A
8/7/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	N/A	N/A	N/A	$8.32 million	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22
PTGX Protagonist Therapeutics	N/A	17.25	17.26
REPH Recro Pharma	2.27	3.24	2.74
ULUR ULURU	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
LXRX Lexicon Pharmaceuticals	74.70%
PTGX Protagonist Therapeutics	98.63%
REPH Recro Pharma	62.34%
ULUR ULURU	N/A

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	5.40%
LXRX Lexicon Pharmaceuticals	13.90%
PTGX Protagonist Therapeutics	4.90%
REPH Recro Pharma	14.20%
ULUR ULURU	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	48.40 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable
ULUR ULURU	2	30.57 million	30.24 million	Not Optionable

LXRX, REPH, ABEO, PTGX, and ULUR Headlines

Recent News About These Companies

National Indigenous Training Academy recognised for its training excellence at Territory awards

July 11 at 12:30 AM | ntnews.com.auN

Virgin Australia cuts low season direct flights between Brisbane and Red Centre

July 10, 2025 | thechronicle.com.auT

GPs Honor Indigenous Leadership During NAIDOC Week

July 7, 2025 | miragenews.comM

‘Unacceptable’: Mutitjulu community waiting 10 years for new housing

July 3, 2025 | skynews.com.auS

Indigenous leaders say Uluru town at centre of Voice Referendum is still waiting for housing after 10 years, as bureaucracy stymies growth

July 3, 2025 | skynews.com.auS

Full 50th NAIDOC schedule for Uluru and Ayers Rock Resort released by Voyages Indigenous Tourism

June 30, 2025 | townsvillebulletin.com.auT

NT Gov backs brand new five day, four night 54km eco walk at Uluru with $10m loan

June 29, 2025 | ntnews.com.auN

10 best Australian road trips to do with a caravan

June 28, 2025 | msn.com

Ugly fight between ‘radical rock climbers’ and traditional owners over world-famous site

June 27, 2025 | news.com.auN

CLP-Backed Eco Walk Enhances Central Australia Experience

June 26, 2025 | miragenews.comM

Virgin Australia sale offers deals on flights in and out of the Territory

June 23, 2025 | ntnews.com.auN

Local 10’s Eco Hero winner’s adventures continue in the Australian Outback

June 23, 2025 | local10.comL

Shadows falling across the land

June 21, 2025 | thewest.com.auT

Uluru with friends

June 21, 2025 | thewest.com.auT

Winter getaways in Queensland: from Brisbane to Cairns and the Great Barrier Reef plus Uluru

June 20, 2025 | theaustralian.com.au

Jess Mauboy always wanted to be a mum. She didn't expect the way it changed her.

June 20, 2025 | msn.com

Uluru Statement from the Heart: All Aboriginal people need access to education, employment and a safe living environments

June 17, 2025 | dailytelegraph.com.auD

Uluru Australia (Mala Walk) Walking Tour

June 16, 2025 | msn.com

Take That! How to sell Australia’s Northern Territory

June 12, 2025 | ttgmedia.comT

10 BEST Places to Visit in Australia in 2024 🇦🇺 | Full Travel Guide by Lloyd & Mandy

June 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, REPH, ABEO, PTGX, and ULUR Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.92 +0.18 (+3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$5.89 -0.03 (-0.49%)

As of 07:56 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.18 +0.10 (+9.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 -0.02 (-2.12%)

As of 07:59 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Protagonist Therapeutics NASDAQ:PTGX

$55.23 +2.23 (+4.21%)

Closing price 04:00 PM Eastern

Extended Trading

$53.74 -1.49 (-2.70%)

As of 05:52 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Recro Pharma NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time